Can digital questionnaires improve life during pancreatic cancer therapy?
NCT ID NCT07829471
First seen Sep 21, 2026 · Last updated Sep 21, 2026
Summary
Researchers at MD Anderson Cancer Center are studying whether routine electronic symptom monitoring improves quality of life and care experience for patients with pancreatic adenocarcinoma receiving chemotherapy or radiation before surgery. About 200 adults with operable or locally advanced pancreatic cancer will use electronic questionnaires to report symptoms during treatment. The study compares patient experiences before and after this monitoring is implemented.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- routine electronic patient-reported outcome symptom monitoring
- What this could lead to
- If it helps, this approach could become a standard way to track symptoms and improve quality of life for people receiving pancreatic cancer treatment.
- What could go wrong
- This is an implementation study, not a randomized trial, so it may not prove that monitoring itself causes better outcomes. Results could be influenced by other changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2027
An estimate. Start dates often move.
- Expected to finish
-
Jul 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility Criteria * Age ≥18 years * Participants must have histologically confirmed PDAC that is respectable, borderline respectable, or locally advanced with potential for curative intent resection as defined by MD Anderson Cancer Center (Appendix V) * Participants must be eligible to receive systemic neoadjuvant therapy (chemotherapy +/- radiation therapy) with intent for curative resection * Participants who will receive neoadjuvant therapy at an MD Anderson facility including Texas Medical Center and Houston area locations * Participants must be able to understand English or Spanish * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria * Definitively unresectable or metastatic disease at enrollment * Participants who received pre-referral chemotherapy, chemoradiotherapy, or previously attempted resection * Participants who had prior curative intent surgery for pancreatic cancer before entering the study * Participant with cognitive deficits that would preclude understanding of consent form and/or questionnaires * Participants with psychiatric illness/social situations that would limit compliance with study requirements * Participants who do not understand English or Spanish * Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia * Participants with uncontrolled underlying medical conditions * Participants receiving chemotherapy outside of the MD Anderson system
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinical outcomes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UT MD Anderson Cancer Center
Houston, Texas, 77044, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI and computer models predict how well cancer drugs reach tumors?
- New chemo cocktail targets pancreatic cancer at every stage
- Can a phone app help pancreatic cancer patients eat better during treatment?
- Can an oral HER2 drug boost Chemo's punch in HER2-Low breast cancer?
- Can a Dietitian's plan help older pancreatic cancer patients feel better?
- Breast Cancer's genetic fingerprint: a new platform aims to match tumors to targeted trials